SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.59-1.1%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (3014)2/28/2001 10:09:05 PM
From: Ian@SI   of 52153
 
Peter,

I just listened to the SCIO presentation given today at the Lehman Biotech conference.

I got the impression that they're able to precisely control dosage substantially reducing risk of undesired toxic side effects. Given that their p38 map kinase inhibitor (SCIO-469) targets a multi-Billion $ market (RA), I still feel it adds some value that is not yet reflected in the stock price. I fully accept that it would be premature to expect much price action prior to safety and efficacy results coming from a Ph III trial - something which I suspect is 2 years +, away.

Nice update and prognosis for Natrecor, as well.

Replay of the presentation is available at: 1 800 625 5288 944626#
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News